CD24 and breast carcinoma: These dual antibody-conjugated nanoreactors demonstrate potential for checkpoint blockade immunotherapy (CBIT) by effectively targeting and blocking PD-L1 and CD24 proteins present on breast cancer cells, specifically TNBC cells.